Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant Human Adenovirus Type 5 Combined With Tislelizumab and Lenvatinib in Advanced Hepatocellular Carcinoma
NCT06253598Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Bengbu Medical University
- Start
- Mar 2024
- Primary completion
- Dec 2025
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
01
Overview
A Phase 2 trial of Oncorine in hepatocellular carcinoma (HCC), sponsored by First Affiliated Hospital of Bengbu Medical University. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
Oncorine
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06253598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06253598.